Can zapping a few spots keep lung cancer in check?
NCT ID NCT04405401
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This trial tests whether precisely targeted radiation (SABR) to a small number of growing tumors, while continuing current drug therapy, can delay overall disease progression in people with metastatic non-small cell lung cancer. About 68 participants whose cancer has started to grow in just 1 to 5 spots will be randomly assigned to receive either SABR plus their ongoing therapy or standard care, which may include switching to a new treatment. The study aims to see if this focused approach can buy more time before the cancer advances further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stereotactic ablative radiotherapy (SABR) to oligoprogressive lesions, plus continuation of current systemic therapy
- What this could lead to
- If successful, this approach could offer a way to extend the effectiveness of current systemic therapy by delaying the need to switch treatments.
- What could go wrong
- This is a small phase II trial, so results may not be definitive. Radiation carries risks like fatigue or damage to nearby organs, and the benefit over standard care is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, H2X 3E4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Surgery for hidden lung cancer spread: a new hope for longer life?
- New drug combo aims to outperform standard care in aggressive lung cancer
- Could a cholesterol drug boost immunotherapy in lung cancer?
- Scientists hunt for clues to why immunotherapy fails in most patients
- New immunotherapy combo shows promise for stage IV lung cancer